SEATTLE--(BUSINESS WIRE)--Aug. 22, 2005--Enrollment is under way for a new research study to study the effectiveness of an investigational agent in patients with bronchioloalveolar carcinoma (BAC), a subtype of non-small cell lung cancer. The PEAK trial is a multicenter, open-label, phase II trial that will be led in Seattle by Dr. Howard West, a leading oncology researcher affiliated with the Swedish Cancer Institute who has participated in several studies of treatments for non-small cell lung cancer.
